1188 infection control & hospital epidemiology october 2015, vol. 36, no. 10
had a prior CDI episode. Finally, PHIS data does not include clinical data. Therefore, we were not able to confirm the pre- sence of recurrent CDI based on the presence of symptoms, as provided in current CDI guidelines;1 instead, we used read- mission for CDI as a proxy for recurrence. Our study identifies several important patient characteristics
that were found to be independent risk factors for in-hospital mortality and CDI-related readmission within 8 weeks. Given the increased incidence of pediatric CDI and recent findings that CDI is associated with increased risk of death among hospitalized children, identifying subgroups of children with CDI who are at higher risk of poor outcomes is crucial and may inform the design of future studies to determine the optimal treatment of CDI in children. In addition, these children may benefit from targeted CDI prevention strategies, such as antibiotic stewardship programs.
acknowledgments
Financial support: This work was supported by Merck Research funding through their investigator initiated studies program. Potential conflicts of interest: NV received research support from Merck. TEZ
has received research support from Merck and has served as a consultant to Merck,Cubist, Astellas, and Pfizer. JSS received funding support throughMerck from their investigator initiated studies program. SEC reports no conflicts.
Address correspondence to Neika Vendetti, MPH, Division of Infectious
Diseases, The Children’s Hospital of Philadelphia, 3535 Market St. Rm 1519, Philadelphia, PA 19104 (
Vendettin@email.chop.edu).
references
1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–455.
2. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29:S81–S92.
3. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children’s hospitals in the United States, 2001–2006. Pediatrics 2008;122:1266–1270.
4. Zilberberg MD, Shorr AF, Kollef MH. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000–2005. Pediatr Infect Dis J 2008;27:1111–1113.
5. Nylund CM, Goudie A, Garza JM, Fairbrother G, Cohen MB. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011;165:451–457.
6. Elliott B, Chang BJ, Golledge CL, Riley TV. Clostridium difficile- associated diarrhoea. Intern Med J 2007;37:561–568.
7. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Gastroenterol Hepatol 2008;5:40–48.
8. Sammons JS, Toltzis P. Recent trends in the epidemiology and treatment of C. difficile infection in children. Curr Opin Pediatr 2013;25:116–121.
9. Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 2013; 57:1–8.
10. Shaklee J, Zerr DM, Elward A, et al. Improving surveillance for pediatric Clostridium difficile infection: derivation and validation of an accurate case-finding tool. Pediatr Infect Dis J 2011;30: e38–e40.
11. Feudtner C, Christakis DA, Zimmerman FJ, Muldoon JH, Neff JM, Koepsell TD. Characteristics of deaths occurring in children’s hospitals: implications for supportive care services. Pediatrics 2002;109:887–893.
12. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PloS One 2014;9:e98400.
13. Hardt C, Berns T, Treder W, Dumoulin FL. Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein. World J Gastroentero 2008;14: 4338–4341.
14. Kim ES, Kim YJ, Park CW, et al. Response failure to the treatment of Clostridium difficile infection and its impact on 30-day mortality. Hepato-gastroenterol 2013;60:543–548.
15. de Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr 2013;163:699–705.
16. Tai E, Richardson LC, Townsend J, Howard E, McDonald LC. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 2011;30:610–612.
17. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infec- tion: a population-based study. Mayo Clin Proc 2012;87:636–642.
18. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated 2989–2995.
disease. JAMA 2005;294:
19. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012;10: 225–2233.
20. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastoenterol 2012;107:1011–1019.
21. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastoenterol 2012;107:1001–1010.
22. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010;31:754–759.
23. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.
24. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluor- oquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140